The burden of neovascular age-related macular degeneration: a patient’s perspective
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: To quantify the burden and quality of life of patients and their caregivers in a cohort of patients with neovascular age-related macular degeneration (nAMD) in an Australian clinical setting. METHODS: A total of 103 patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for nAMD were asked to complete questionnaires relating to the financial and time burdens of nAMD. RESULTS: All patients completed the questionnaires. Loss in productivity due to attendance of appointments was 4.4±1.7 hours per month, with additional time lost by caregivers. Financial strain was incurred by direct medical costs associated with intravitreal assessment and injections at an average of AU$199.2±$83.1 per month. Indirect costs incurred averaged $64.8±$79.7 per month. Qualitative indirect costs due to loss of productivity for the patient, unpaid caregivers, and loss of productivity due to premature mortality were also a considerable burden. Overall mean Visual Function Questionnaire and EuroQol 5D-3L scores were correlated with visual acuity and demonstrated patients' subjective decline in quality of vision. CONCLUSION: Management of nAMD carries a substantial burden on patients and caregivers. These results provide important information in understanding the effect of anti-VEGF therapy among patients with nAMD. Together with the quality-of-life burden on the patients, the management of nAMD has a significant societal impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Evans, J. R., & Lawrenson, J. G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000254.pub4 · Cited by 335
Boyle, J., Vukicevic, M., Koklanis, K., Itsiopoulos, C., & Rees, G. (2018) · Psychology, Health & Medicine · doi:10.1080/13548506.2016.1274040 · Cited by 119
Bandello, F., Augustin, A., Sahel, J.-A., Benhaddi, H., Negrini, C., Hieke, K., & Berdeaux (2008) · Drugs & Aging · doi:10.2165/00002512-200825030-00007 · Cited by 19 · cited 1×
“The burden on patients has been extensively researched, documenting the significant magnitude of medical and nonmedical costs among nAMD patients.(17,18) However, the precise costs that anti-VEGF therapies impose on caregivers remain poorly defined.”
Cited by
The economics of vision impairment and its leading causes: A systematic review
Marques, A. P., Ramke, J., Cairns, J., Butt, T., Zhang, J. H., Jones, I., Jovic, M., Nandakumar, A., Faal, H., Taylor, H., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101354 · Cited by 137
Zhao, X., Seah, I., Xue, K., Wong, W., Tan, Q. S. W., Ma, X., Lin, Q., Lim, J. Y. C., Liu, Z., Parikh, B. H., et al. (2022) · Advanced Materials · doi:10.1002/adma.202108360 · Cited by 84
Patel, P. J., Ziemssen, F., Ng, E., Muthutantri, A., Silverman, D., Tschosik, E. A., & Cantrell, R. A. (2020) · Clinical Ophthalmology · doi:10.2147/opth.s226425 · Cited by 61
“The NEI-VFQ-25 scores reported herein were also lower (ie, poorer) than previously reported in patients with neovascular AMD in two ranibizumab clinical trials (MARINA and ANCHOR) at baseline, as well as in a cross-sectional, non-interventional study in patients undergoing anti–vascular endothelial growth factor thera…”
ResultFernández-Vigo, J. I., Burgos-Blasco, B., Calvo-González, C., Escobar-Moreno, M. J., Shi, H., Jiménez-Santos, M., Valverde-Megías, A., Reche-Frutos, J., López-Guajardo, L., & Donate-López, J. (2021) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2020.11.010 · Cited by 8
Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain
Abraldes, M. J., Calvo, P., Gámez Lechuga, M., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Ruiz-Moreno, J. M. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-00960-9 · Cited by 6
“…vision may impair the patient’s activities of daily living (e.g., self-care, shopping, driving, etc.), leisure activities (e.g., watching television, reading, etc.), as well as work productivity for both patients and caregivers [9, 10], causing an important burden for families and society at large.”
Metadata
- Authors
- Spooner, K., Mhlanga, C., Hong, T., Broadhead, G., & Chang, A.
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2018-12
- Volume
- Volume 12
- Pages
- 2483-2491
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- OpenAlex
- W2903394579
- Cited by
- 121
- References
- 4
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.